Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omega-3 in Treatment Resistant Depression
NCT05774665Phase 2Active, not recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Jan 2025
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eicosapentaenoic acid in treatment-resistant depression (TRD), sponsored by Massachusetts General Hospital. Started Jan 2025; status: active, not recruiting.
02
Drugs
eicosapentaenoic acid
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT05774665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05774665.